会议专题

Differential Effect of MMSET mRNA Levels on Survival to First-line FOLFOX and Second-line Docetaxel in Gastric Cancer

BACKGOURND: BRCA1 expression differentially affects outcome to platinum-and taxane-based chemotherapy.MDC1, 53BP1, MMSET and UBC9 are involved in DNA repair and could modify the BRCA1 predictive model.MOTHODS: MDC1, 53BP1, MMSET and UBC9 mRNA was assessed in gastric tumors from patients in whom BRCA1 levels had previously been determined.RESULTS: In vitro chemosensitivity assay, MMSET levels were higher in docetaxel-sensitive samples.In a separate cohort, survival was longer in those with low MMSET (12.3 vs 8.8 months;P=0.04) or UBC9 (12.4 vs 8.8 months;P=0.01) in patients receiving only FOLFOX.Conversely, among patients receiving second-line docetaxel, longer survival was associated with high MMSET (19.1 vs 13.9 months;P=0.003).Patients with high MMSET and BRCA1 attained a median survival of 36.6 months, compared to 13.9 months for those with high BRCA1 and low MMSET (P =0.003).In the multivariate analyses, low MMSET (HR, 0.59;P =0.04) and low UBC9 (HR, 0.52;P=0.01) levels were markers of longer survival to first-line FOLFOX, while palliative surgery (HR, 2.47, P=0.005), low BRCA1 (HR, 3.17, P=0.001), and low MMSET (HR, 2.52, P=0.004) levels were markers of shorter survival to second-line docetaxel.CONCLUSIONS: BRCA1, MMSET and UBC9 can be useful for customizing chemotherapy in gastric cancer patients.

Jia Wei Jie Shen Lixia Yu Xiaoping Qian Xia Sun Zhengyun Zou Baorui Liu

南京大学医学院附属鼓楼医院肿瘤中心

国内会议

第八届中国肿瘤内科大会、第三届中国肿瘤医师大会暨中国抗癌协会肿瘤临床化疗专业委员会2014年学术年会

北京

英文

545-545

2014-07-02(万方平台首次上网日期,不代表论文的发表时间)